Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win ...
A new analysis presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) examined daily oral ...
A post hoc analysis of phase 3 pivotal data demonstrated sustained symptom improvements in patients with dry eye disease who ...
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
A daily oral therapy reduced insulin-like growth factor I levels and improved symptoms in a real-world setting among adults ...
A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
The impact of nutritional status on recurrence-free survival (RFS) in patients with locally advanced oesophagogastric adenocarcinoma (LA-OGA) treated with FLOT therapy. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results